Novavax stock is soaring on news the FDA set a deadline by which to approve or reject its COVID-19 vaccine.
Shares of Novavax (NVAX) are surging after the company announced it will meet delivery expectations for the fall COVID vaccine push. All COVID vaccines will use the JN.1 strain, part of the Omicron subvariant family. The FDA also set a final date for fully approving the company's COVID vaccine beyond its emergency use authorization. Anjalee Khemlani joins the Morning Brief to break down the details. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This article was written by Gabriel Roy
Novavax stock zipped higher and then plunged Thursday after the FDA set a potential approval date for its Covid vaccine in April.